Spruce Biosciences
SPRB
41 hedge funds and large institutions have $225M invested in Spruce Biosciences in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 40 → 41 (+1)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $313M → $225M (-$87.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$29.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.58M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$1.31M |
| 4 |
Morgan Stanley
New York
|
+$1.26M |
| 5 |
BlackRock
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.13M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$6.76M |
| 3 |
SCM
Sio Capital Management
New York
|
-$2.36M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.13M |
| 5 |
Millennium Management
New York
|
-$794K |
SPRB Hedge Fund Activity: Q2 2021 in Review
41 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2021, worth a combined $225M — down 28% from $313M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SPRB positions and 4 closed out — a net gain of 1 holder — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $29.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $8.13M sold.
- 41 institutional investors held Spruce Biosciences (SPRB) as of Q2 2021, up from 40 in Q1 2021.
- Funds reported $225M of Spruce Biosciences stock for Q2 2021, down 28% quarter-over-quarter.
- 5 funds opened new Spruce Biosciences positions in Q2 2021 and 4 closed out, a net change of +1 holder.
- The largest Spruce Biosciences buyer in Q2 2021 was Deerfield Management, an estimated $29.1M added.
- The largest Spruce Biosciences seller in Q2 2021 was PFM Health Sciences, an estimated $8.13M sold.
Based on aggregated 13F filings for Q2 2021.